Magnitude Biosciences utilizes the nematode C. elegans as a model organism to conduct high-throughput assays for drug development, focusing on areas such as neurodegeneration, toxicity, and aging research. Their services provide researchers with reproducible data on compound efficacy and safety, significantly accelerating the preclinical research process.
Funding
$950.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FDNMFounders
Product
Problem
Drug development and research rely on preclinical data to assess compound efficacy and safety, but traditional methods using in vitro and mammalian models can be time-consuming, costly, and ethically challenging. There is a need for faster, more cost-effective, and ethical methods for generating reproducible in vivo data during preclinical research.
Solution
Magnitude Biosciences offers contract research services utilizing the nematode C. elegans as an in vivo model organism to accelerate preclinical research. Their customized C. elegans studies generate high-quality, reproducible data on compound efficacy and safety across various research areas, including neurodegeneration, toxicity, microbiome, and aging. By leveraging their patented WormGazer™ technology, they provide a multi-faceted healthspan approach, enabling researchers to obtain rich, customizable data and insights into the mechanisms of action of their compounds. This approach allows for faster, more cost-efficient, and ethical primary-stage testing, reducing the need for extensive mammalian testing and de-risking the transition from in vitro studies to mammalian models.
Target Audience
Magnitude Biosciences serves biotechnology, pharmaceutical, health and nutrition, and cosmeceutical companies, as well as academic researchers, seeking to accelerate their preclinical research and generate robust in vivo data on compound efficacy and safety.
Features
- High-throughput screening using C. elegans models for various research areas, including aging, neurodegeneration, toxicity, and microbiome studies.
- Patented WormGazer™ technology for automated, continuous monitoring and data collection on living worms.
- Customizable C. elegans studies tailored to specific research questions and compound characteristics.
- Multi-faceted healthspan approach providing rich, integrated measures on the effect of compounds or products.
- Transgenic services to generate custom C. elegans strains tailored to specific project needs.
- Expertise in target identification and mechanism of action studies using genetic and molecular tools.
- Acute and chronic toxicity testing using C. elegans models.